Table 2.
Outcome measure | Overall, n = 5146 | GLP-1 agonist, n = 2435 | SGLT2 inhibitor, n = 2711 |
---|---|---|---|
30 days | 1637 (31.8%) | 726 (29.8%) | 911 (33.6%) |
14 days | 2099 (40.8%) | 950 (39%) | 1149 (42.4%) |
7 days | 2343 (45.5%) | 1067 (43.8%) | 1276 (47.1%) |
Outcome measure | Overall, n = 5146 | GLP-1 agonist, n = 2435 | SGLT2 inhibitor, n = 2711 |
---|---|---|---|
30 days | 1637 (31.8%) | 726 (29.8%) | 911 (33.6%) |
14 days | 2099 (40.8%) | 950 (39%) | 1149 (42.4%) |
7 days | 2343 (45.5%) | 1067 (43.8%) | 1276 (47.1%) |